FDA Approves Loncastuximab for Diffuse Large B-Cell Lymphomas medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.
KEYTRUDA
® is an anti-PD-1 therapy that works by helping increase the ability of the body s immune system to help detect and fight tumour cells.
1
An estimated 26,900 Canadians were diagnosed with colorectal cancer in 2020, with an average of 73 Canadians diagnosed daily.
2
KIRKLAND, QC, March 8, 2021 /CNW/ - Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that Health Canada has approved KEYTRUDA
® (pembrolizumab), Merck s anti-PD-1 therapy, for the first-line treatment, as monotherapy, for adult patients with metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC).
3 This approval offers a new first-line treatment option for patients with MSI-H/dMMR metastatic colorectal cancer, said Dr. Ron Burkes, Professor of Medicine, University of Toronto and Medical Oncologist, Mount Sinai Hospital.
Approval Based on Significant Progression Free Survival Findings from Phase 3 KEYNOTE-177 Trial KEYTRUDA ® is an anti-PD-1 therapy that works by helping increase the ability of the body’s immune system to help detect and fight tumour cells. 1 An estimated 26,900 Canadians were diagnosed with colorectal cancer in 2020, with an average of 73 Canadians diagnosed daily. 2 Merck known as MSD outside the United States … Approval Based on Significant Progression Free Survival Findings from Phase 3 KEYNOTE-177 Trial KEYTRUDA ® is an anti-PD-1 therapy that works by helping increase the ability of the body’s immune system to help detect and fight tumour cells. 1 An estimated 26,900 Canadians were diagnosed with colorectal cancer in 2020, with an average of 73 Canadians diagnosed daily.
(2)
KEYTRUDA Is First Checkpoint Inhibitor Approved in Europe to Treat MSI-H or dMMR Colorectal Cancer
European Approval Based on Results From KEYNOTE-177 Trial Demonstrating KEYTRUDA Significantly Reduced Risk of Disease Progression or Death by 40% Compared With Chemotherapy
Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the European Commission has approved KEYTRUDA, Merck s anti-PD-1 therapy, as a monotherapy for the first-line treatment of adult patients with metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer. This approval is based on results from the pivotal Phase 3 KEYNOTE-177 trial, in which KEYTRUDA monotherapy significantly reduced the risk of disease progression or death by 40% (HR=0.60 [95% CI, 0.45-0.80]; p=0.0002) compared with chemotherapy (investigator s choice: mFOLFOX6 [oxaliplatin, leucovorin and fluorouracil (FU)] with or without bevacizumab or cetuximab; or FOLFIR
İsmet İnönü 47 ölüm yıl dönümünde anılıyor sozcu.com.tr - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sozcu.com.tr Daily Mail and Mail on Sunday newspapers.